An NIH Scientist with Ties to Big Pharma Retracted a Journal Study Showing COVID Injections May Cause Cancer, according to Emails Compelled through FOIA Request

From [HERE] and [HERE] A recent investigation by Australian journalist Rebekah Barnett suggests politics and financial interests, not scientific concerns, led to the retraction of a 2021 peer-reviewed study finding the spike protein from SARS-CoV-2 and the mRNA vaccine impair critical DNA repair mechanisms, which could lead to cancer.

Viruses, published by MDPI, retracted the study in 2022, despite objections by the lead author, Ya-Fang Mei, Ph.D., of Sweden’s Umeå University.

Subsequent research and case studies have largely validated the findings of the retracted study conducted by Mei and Hui Jiang, Ph.D., of Stockholm University in Sweden.

Barnett’s investigation, built on work by independent journalist John Davidson and Dr. Ah Kahn Syed, included emails released under the Freedom of Information Act (FOIA) revealing that Eric O. Freed, Ph.D., editor-in-chief of Viruses, oversaw its retraction.

Freed, a scientist with the National Institutes of Health (NIH), suggested the retraction could proceed without evidence of scientific misconduct, raising questions about his impartiality.

The study’s co-author originally requested the retraction. However, Mei strongly objected, claiming Stockholm University “forced” the retraction due to external pressure.

The NIH rejected Davidson’s FOIA request for Freed’s emails related to the retraction, citing trade secret exemptions. However, Barnett’s FOIA to Stockholm University uncovered some of these emails.

Barnett’s article contains images of many FOIA’d emails describing the progression of arguments among various scientists and journal and university personnel leading up to the retraction.

Retracted paper showed spike protein could cause cancer

Mei and Jiang found that the SARS-CoV-2 spike protein — and its mRNA-vaccine-derived analog — significantly inhibits DNA damage repair, which is essential for maintaining genomic stability and preventing cancer.

The researchers demonstrated that the spike protein localizes in the cell nucleus and inhibits DNA repair by hindering the recruitment of key repair proteins BRCA1 (breast cancer type 1 susceptibility protein) and 53BP1 (p53-binding protein 1) to the damage site.

The spike protein’s suppression of the p53 gene, known as the “guardian of the genome,” is particularly concerning, as the gene is crucial in preventing cancer development — particularly, breast, ovarian and other cancers affecting women.

Moreover, the study found that the spike protein impairs V(D)J recombination, a complex genetic process occurring in the early stages of T and B lymphocyte development, which are key components of the adaptive immune system.

This process is essential for generating a diverse repertoire of T-cell receptors and antibodies (immunoglobulins) that can recognize and combat a wide range of pathogens. [MORE]